Andere talen NanoViricides, Inc.

Aandelen

NNVC

US6300873022

Beurs gesloten - Nyse Andere beurzen 22:00:00 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,4 ^USD	+23,89%		+23,89%	+37,25%

30/04	NanoViricides, Inc. meldt dat de Fase I klinische studie van NV-387 met succes is voltooid en dat de gegevens binnenkort worden vergrendeld	CI
14/02	NanoViricides, Inc. rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon	01/05
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	30/04
NanoViricides: Fiscal Q2 Earnings Snapshot	14/02
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications beyond COVID Treatment, Explains NanoViricides, NV-387 Could be As Revolutionary as Antibiotics	02/02
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	01/02
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides	30/01
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found	29/01
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387	29/11
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2	28/11
NanoViricides Has Filed its Quarterly Report, NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications	16/11
NanoViricides, Inc. - Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development	15/11
NanoViricides: Fiscal Q1 Earnings Snapshot	15/11
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development	14/11
North American Morning Briefing : Geopolitical -2-	18-10-23
NanoViricides, Inc. Has Filed its Annual Report	17-10-23
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	13-10-23
North American Morning Briefing : Stock Futures -2-	11-10-23
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant	27-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NanoViricides, Inc.

Aandelen

NNVC

US6300873022

Andere talen

Filters